摘要
目的对照探讨气管滴入不同初始量肺表面活性物质对于新生儿呼吸窘迫综合征疗效差异。方法选取2013年5月-2018年6月我院收治的28-34周的新生儿呼吸窘迫综合征新生儿96例,随机分为两组,对照组患儿给予70mg/Kg起始量、肺表面活性物质(pulmonarysurfactant,PS)经气管滴入治疗,观察组起始量为100mg/Kg,每组各48例。对患儿动脉血气、治疗费用、用药后并发症等情况进行统计分析,对比两组疗效差异。结果使用PS后同一时间段观察组FiO2显著更低,P<0.05。使用PS后1、12、24h测定PaO2值,对照组显著较低,P<0.05。使用PS后一小时内,两组患儿PaCO2无明显差别,P>0.05,12h与24h两组对比差异较大,P<0.05。使用PS前后NRDS0、4级分期数据两组不见显著差异,P>0.05。使用PS治疗后,NRDS1、2、3期对照组患儿比例均显著高于观察组,P<0.05。观察组机械通气时间及用氧时间显著较低,P<0.05。结论100mg/kg起始量PS疗效更佳,可作为临床治疗的优先选择。
Objective To investigate the effect of tracheal instillation of different initial doses of pulmonary surfactant on neonatal respiratory distress syndrome.Methods 96 neonates with neonatal respiratory distress syndrome from 28 to 34 weeks admitted to our hospital from May 2013 to June 2018 were randomly divided into two groups.The control group received 70 mg/Kg of starting lung.The surfactant(PS)was treated by tracheal instillation.The initial amount of the observation group was 100 mg/Kg,48 cases in each group.Statistical analysis was performed on the arterial blood gas,treatment cost,and post-medication complications of the children,and the difference in efficacy between the two groups was compared.Results The level of FiO 2 was significantly lower in the observation group at the same time period after PS(P<0.05).The PO2 value was measured at 1,12,and 24 h after PS,and the control group was significantly lower(P<0.05).There was no significant difference in PCO2 between the two groups within one hour after PS administration(P>0.05),but it showed significant differences 12h and 24h after PS(P<0.05).There was no significant difference between the two groups in the NRDS 0 and 4 staging data before and after PS(P>0.05).After treatment with PS,the proportion of children in the NRDS 1,2,and 3 control groups was significantly higher than that in the observation group(P<0.05).The mechanical ventilation time and oxygen consumption time of the observation group were significantly lower(P<0.05).Conclusion The initial dose of 100 mg/kg is more effective and can be used as a priority for clinical treatment.
作者
庄加原
潘浩
方慧
ZHUANG Jia-yuan;PAN Hao;FANG Hui(Department of Pediatrics,Huangshan People's Hospital,Huangshan,Anhui245000,China)
出处
《临床肺科杂志》
2019年第6期1038-1042,共5页
Journal of Clinical Pulmonary Medicine
关键词
肺表面活性物质
新生儿呼吸窘迫综合征
气管滴入
疗效
pulmonary surfactant
neonatal respiratory distress syndrome
tracheal instillation
efficacy
